Observational Study to Assess the Efficacy and Safety of NovoRapid™ Flexpen™

Novo Nordisk A/S373 enrolled

Overview

This study is conducted in Asia. The aim of this observational study is to collect efficacy and safety data in diabetic patients with acute hyperglycemia using NovoRapid™ FlexPen™ as per normal clinical practice.

Study Type

OBSERVATIONAL

Enrollment

373

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Delivery Systems

Interventions

insulin aspartDRUG

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with diabetes mellitus (according to product labelling) Exclusion Criteria: * Hypoglycaemia * Hypersensitivity to insulin aspart or to any of the excipients (according to product labelling)

Locations (1)

Novo Nordisk Investigational Site

Manila, Philippines

Outcomes

Primary Outcomes

Safety profile of Insulin Aspart among Filipino patients

Time frame: 1-month follow-up for outpatients; 1 month or upon discharge for inpatients whichever comes first

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.